ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.59
1.05%
US Tech 100
20,332.80
1.61%
S&P 500
5,954.50
1.59%
US Dollar vs CAD
1.44675
0.00%
Bitcoin
86,228.01
2.21%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Penumbra Inc (PEN) Share Price

Penumbra Inc

Penumbra Inc (PEN)

Peninsula Energy Ltd
Pennant International Group Plc
PBF Energy Inc
285.44
3.98
(1.41%)
Closed February 28 3:00PM
Delayed by 15 minutes
285.44
0.00
(0.00%)
After Hours: 4:30PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
285.44
Bid
-
Ask
-
Volume
323,048
278.41 Day's Range 285.44
148.00 52 Week Range 310.00
Market Cap
10.994B
Previous Close
281.46
Open
280.22
Last Trade
72912
@
285.44
Last Trade Time
Financial Volume
US$ 91,098,854
VWAP
281.9979
Average Volume (3m)
458,831
Shares Outstanding
38,515,949
Dividend Yield
-
PE Ratio
784.61
Earnings Per Share (EPS)
0.36
Revenue
1.19B
Net Profit
14.01M

About Penumbra Inc

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurova... Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.penumbrainc.com
Headquarters
Dover, Delaware, USA
Founded
-
Penumbra Inc is listed in the Surgical,med Instr,apparatus sector of the New York Stock Exchange with ticker PEN. The last closing price for Penumbra was US$281.46. Over the last year, Penumbra shares have traded in a share price range of US$ 148.00 to US$ 310.00.

Penumbra currently has 38,515,949 shares outstanding. The market capitalization of Penumbra is US$10.84 billion. Penumbra has a price to earnings ratio (PE ratio) of 784.61.

Ask ADVFN Intelligence (AI)

PEN Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
February 21 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 19 2025
PEN (1.41%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-17.56-5.79537953795303304.11275.27501930287.33234076CS
415.375.69111711778270.07310258.82564665279.8454304CS
1240.7116.6346586034244.73310222.59458831264.48649886CS
2682.0840.3619197482203.36310184.8399693238.60902091CS
5253.2322.9232160544232.21310148399608218.24178743CS
15663.7328.7447566641221.71348.67114.865371075222.13909324CS
260115.0767.5412337853170.37348.67114.865355245223.13684548CS

PEN - Frequently Asked Questions (FAQ)

What is the current Penumbra share price?
The current share price of Penumbra is US$ 285.44
How many Penumbra shares are in issue?
Penumbra has 38,515,949 shares in issue
What is the market cap of Penumbra?
The market capitalisation of Penumbra is USD 10.84B
What is the 1 year trading range for Penumbra share price?
Penumbra has traded in the range of US$ 148.00 to US$ 310.00 during the past year
What is the PE ratio of Penumbra?
The price to earnings ratio of Penumbra is 784.61
What is the cash to sales ratio of Penumbra?
The cash to sales ratio of Penumbra is 9.2
What is the reporting currency for Penumbra?
Penumbra reports financial results in USD
What is the latest annual turnover for Penumbra?
The latest annual turnover of Penumbra is USD 1.19B
What is the latest annual profit for Penumbra?
The latest annual profit of Penumbra is USD 14.01M
What is the registered address of Penumbra?
The registered address for Penumbra is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the Penumbra website address?
The website address for Penumbra is www.penumbrainc.com
Which industry sector does Penumbra operate in?
Penumbra operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OMIOwens and Minor Inc
US$ 9.60
(39.33%)
12.11M
TPCTutor Perini Corporation
US$ 29.44
(34.61%)
1.87M
OCFTOneConnect Financial Technology Co Ltd
US$ 5.32
(22.34%)
1.41M
ARLOArlo Technologies Inc
US$ 14.38
(20.64%)
3M
PRGOPerrigo Company Plc Ireland
US$ 29.01
(20.22%)
7.58M
DVDoubleVerify Holdings Inc
US$ 13.895
(-36.06%)
14.92M
AMRCAmeresco Inc
US$ 11.80
(-35.62%)
3.51M
KINDNextdoor Holdings Inc
US$ 1.765
(-29.12%)
15.96M
EBEventbrite Inc
US$ 2.42
(-21.94%)
5.66M
FEDUFour Seasons Education Cayman Inc
US$ 8.26
(-21.71%)
5.21k
LYGLloyds Banking Group Plc
US$ 3.74
(1.36%)
243.89M
NUNu Holdings Ltd
US$ 10.75
(-4.44%)
139.76M
FFord Motor Company
US$ 9.54
(2.69%)
137.99M
BCSBarclays PLC
US$ 15.87
(1.15%)
100.07M
AESAES Corp
US$ 11.59
(11.66%)
71.51M

PEN Discussion

View Posts
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
... ALL NEWS IS GOOD? ... $PEN



CNBC's Scott Wapner reports on why Quintessential Capital Management is shorting Penumbra and why it's questioning the safety of its medical devices.

👍️0
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
QCM legal team filed detailed reports with allegations of misconduct with FDA, SEC and other institutions urging thorough investigation
Deceptive behavior would point to lack of integrity unworthy of management leading $10bn healthcare company and may explain Jet7 crisis leading to multiple deaths, injuries
QCM calls on Adam Elsesser, Arani Bose to resign at once if allegations confirmed
Situation constitutes existential threat to Penumbra’s viability as a public company
👍️0
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
Executive Summary

Large portion of scientific literature produced by Penumbra appears authored by fake character in sophisticated, multi-year deception
Fake character seems fabricated by Penumbra’s management attempting to hide involvement in research with significant undisclosed conflicts of interest
Conflicted research used extensively to market products to healthcare providers, to support FDA applications and to promote stock in IPO
Legal advisers: behavior, if confirmed, may constitute serious fraud threatening revocation of FDA clearances, SEC enforcement and litigation from clients
👍️0
davidsson10 davidsson10 4 years ago
https://www.qcmfunds.com/penumbra-and-its-killer-catheter/?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link
👍️0
@LaughinPaulRyan @LaughinPaulRyan 4 years ago
... ROFLMFAO ... $PEN

Penumbra Inc
Penumbra, Inc. designs, develops, manufactures, and markets medical devices. The Company offers peripheral vascular and neurovascular devices that help patients suffering from stroke and other neurovascular diseases. Penumbra operates in the United States.
CURRENT PRICE

PEN:US197.48USD-26.54-11.85%AS OF 10:55 AM EST 12/08/2020
👍️0
TREND1 TREND1 10 years ago
IPO INFO

http://www.marketwatch.com/tools/ipo-calendar
👍️0
TREND1 TREND1 10 years ago
IPO NOW HAS SYMBOL
Penumbra PEN
👍️0
TREND1 TREND1 10 years ago
IPO should be out soon.
no symbol yet.
👍️0

Your Recent History

NYSE
PEN
Penumbra
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads